An advisory panel of the Food and Drug Administration stated today that virtually all over-the-counter decongestants simply don’t work. The FDA panel found that phenylephrine — the active ...

The drug, known as phenylephrine, was previously a go-to drug for sinus pressure and congestion, after another nasal decongestant known as pseudoephedrine had its availability restricted.

Just before cold and flu season is set to kick off, the Food and Drug Administration's advisory panel last month reported that an oral decongestant Americans have relied on for nearly 20 years is ...

Phenylephrine, the key drug used in leading decongestant brands such as Sudafed, Allegra and Dayquil, is nothing more than a placebo when taken orally, according to the latest research from a Food ...

The FDA considered taking phenylephrine off the market in 2007, but ultimately decided it could stay while more research was done. One possibility was to test larger doses of the drug.

That’s because pseudoephedrine can be used to manufacture the street drug methamphetamine. Medicated nasal sprays, including those containing phenylephrine, can also relieve nasal congestion.

The FDA proposed discontinuing the use of phenylephrine, an ingredient in common medications like Sudafed, because it 'is not effective' in treating cold and flu symptoms.

Left: Cold and flu medicine sits on a store shelf on Sept. 12, 2023 in Miami, Florida. The Food and Drug Administration advisory panel announced that an ingredient in many over-the-counter cold ...

A Food and Drug Administration (FDA) advisory committee unanimously voted Tuesday that current scientific data does not support the use of the active ingredient in over-the-counter products like Su… ...

Pseudoephedrine is a drug commonly used to treat nasal congestion. Some Sudafed products contain additional ingredients, such as acetaminophen or naproxen. People commonly use Sudafed to treat: ...

The decongestant was originally approved by the FDA in 1976, ... While the panel upheld the drug's approval, it concluded that more studies were needed for a full assessment.

In a long-sought move, the Food and Drug Administration on Thursday formally began the process of abandoning oral doses of a common over-the-counter decongestant, which the agency concluded last ...